As of 2026-04-02, the EV/EBITDA ratio of Beam Therapeutics Inc (BEAM) is -6.01. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BEAM's latest enterprise value is 2,172.11 mil USD. BEAM's TTM EBITDA according to its financial statements is -361.22 mil USD. Dividing these 2 quantities gives us the above BEAM EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.2x - 14.6x | 14.4x |
| Forward P/E multiples | 17.9x - 21.3x | 20.0x |
| Fair Price | (60.58) - (49.02) | (58.10) |
| Upside | -350.1% - -302.4% | -339.9% |
| Date | EV/EBITDA |
| 2026-03-27 | -5.44 |
| 2026-03-26 | -5.84 |
| 2026-03-25 | -5.70 |
| 2026-03-24 | -5.94 |
| 2026-03-23 | -6.28 |
| 2026-03-20 | -6.13 |
| 2026-03-19 | -6.28 |
| 2026-03-18 | -6.32 |
| 2026-03-17 | -6.47 |
| 2026-03-16 | -6.37 |
| 2026-03-13 | -6.28 |
| 2026-03-12 | -6.40 |
| 2026-03-11 | -6.54 |
| 2026-03-10 | -6.54 |
| 2026-03-09 | -6.97 |
| 2026-03-06 | -6.67 |
| 2026-03-05 | -6.38 |
| 2026-03-04 | -6.92 |
| 2026-03-03 | -6.86 |
| 2026-03-02 | -7.27 |
| 2026-02-27 | -7.21 |
| 2026-02-26 | -7.34 |
| 2026-02-25 | -7.53 |
| 2026-02-24 | -8.29 |
| 2026-02-23 | -7.17 |
| 2026-02-20 | -6.96 |
| 2026-02-19 | -7.05 |
| 2026-02-18 | -6.96 |
| 2026-02-17 | -6.94 |
| 2026-02-13 | -7.06 |
| 2026-02-12 | -6.78 |
| 2026-02-11 | -6.51 |
| 2026-02-10 | -6.78 |
| 2026-02-09 | -6.88 |
| 2026-02-06 | -6.66 |
| 2026-02-05 | -6.16 |
| 2026-02-04 | -6.78 |
| 2026-02-03 | -7.05 |
| 2026-02-02 | -7.06 |
| 2026-01-30 | -6.97 |
| 2026-01-29 | -7.44 |
| 2026-01-28 | -7.37 |
| 2026-01-27 | -7.84 |
| 2026-01-26 | -7.91 |
| 2026-01-23 | -8.08 |
| 2026-01-22 | -8.84 |
| 2026-01-21 | -7.96 |
| 2026-01-20 | -7.92 |
| 2026-01-16 | -7.99 |
| 2026-01-15 | -8.22 |